论文部分内容阅读
ＡＰ９２１具有明显的拮抗血小板活化因子（ＰＡＦ）作用。体外实验表明，ＡＰ９２１水提取物对ＰＡＦ诱导的血小板聚集功能有显著的抑制作用，抑制率为８１．５％，与银杏内酯Ｂ（同期对照）的抑制作用相似。体内实验表明，受试者口服ＡＰ９２１水提取物和醇提取物后，ＰＡＦ诱导的血小板聚集率显著下降。醇提取物对花生四烯酸（ＡＡ）诱导的血小板聚集亦有抑制作用，而水提取物只表现为对ＰＡＦ的抑制作用，提示ＡＰ９２１中含有较特异的ＰＡＦ拮抗成分。ＡＰ９２１抗ＰＡＦ作用的发现为该药抗风湿作用的机理和研究该药有效成分奠定了基础，并为ＰＡＦ拮抗剂的开发增添了新内容。
AP921 has obvious antagonistic effect on platelet activating factor (PAF). In vitro experiments showed that AP921 water extract significantly inhibited PAF-induced platelet aggregation with an inhibitory rate of 81.5%, which was similar to that of Ginkgolide B (same period control). In vivo experiments showed that PAF-induced platelet aggregation decreased significantly after oral administration of AP921 water extract and alcohol extract. Alcohol extract also inhibited arachidonic acid (AA) -induced platelet aggregation, while water extract showed only inhibitory effect on PAF, suggesting that AP921 contains more specific PAF antagonistic components. The discovery of the anti-PAF effect of AP921 has laid the foundation for the anti-rheumatic mechanism of the drug and studied the active ingredients of the drug, and added new content for the development of PAF antagonists.